Offices of the Green Cross company in Osaka, Japan, have been raided by Japanese prosecutors on suspicion of professional negligence which resulted in deaths connected to the sale by the firm of HIV-tainted blood products (Marketletters passim).
The raid marked the start of criminal investigations of drug companies involved in the scandal. The five companies involved and the Japanese government recently reached an out-of-court settlement with those who contracted the virus as a result of using the contaminated products.
Meantime in the USA, Green Cross' wholly-owned subsidiary Alpha Therapeutic is expected to pay around $90 million in damages for supplying HIV-contaminated blood products in the USA, under a settlement reached in a northern Illinois federal court. Hemophiliacs had sued Alpha and three other US firms and have accepted a settlement worth $100,000 in compensation for each of the 600 or so plaintiffs. The American Center for Disease Control estimates that around 6,000 hemophiliacs were infected, which could raise total damages for the four drug companies to $600 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze